journal
Journals Seminars in Thrombosis and Hem...

Seminars in Thrombosis and Hemostasis

https://read.qxmd.com/read/38950598/pharmacotherapy-for-venous-thromboprophylaxis-following-total-hip-or-knee-arthroplasty-a-systematic-review-and-network-meta-analysis
#1
JOURNAL ARTICLE
Bryan Song Jun Yong, Ryan Ruiyang Ling, Ruiqi Li, Jane Wenjin Poh, Chuen Seng Tan, Sean Wei Loong Ho, Bram Rochwerg, Roopen Arya, Kollengode Ramanathan, Bingwen Eugene Fan
The optimal pharmacological prophylaxis for venous thromboembolism (VTE) after hip or knee arthroplasty is uncertain. We conducted a systematic review and network meta-analysis to compare the efficacy and safety of various medications. We searched multiple databases for randomized clinical trials (RCTs) comparing medications (including factor Xa inhibitors, factor IIa inhibitor, warfarin, unfractionated heparin [UFH], low-molecular-weight heparin [LMWH], aspirin, pentasaccharide) for VTE prophylaxis post-arthroplasty...
July 1, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38950597/current-diagnosis-of-von-willebrand-disease-in-italy-3-years-following-the-release-of-the-international-guidelines
#2
JOURNAL ARTICLE
Augusto B Federici
The American Society of Hematology-International Society on Thrombosis and Haemostasis-National Hemophilia Foundation-World Federation of Hemophilia 2021 International Guidelines (IGL) on von Willebrand disease (VWD) have pointed out many challenges, mainly in the diagnostic approach of VWD patients. To determine the impact of these IGL on the current clinical and laboratory diagnosis of Italian VWD patients, we have recently conducted a survey among 43 centers affiliated with the Italian Association of Hemophilia Centers (AICE)...
July 1, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38950596/point-of-care-testing-in-patients-with-hereditary-disorders-of-primary-hemostasis-a-narrative-review
#3
JOURNAL ARTICLE
Aernoud P Bavinck, Waander van Heerde, Saskia E M Schols
Inherited disorders of primary hemostasis, such as von Willebrand disease and congenital platelet disorders, can cause extensive, typically mucocutaneous bleeding. Assays to diagnose and monitor these disorders, such as von Willebrand factor activity assays and light transmission aggregometry, are performed in specialized hemostasis laboratories but are commonly not available in local hospitals. Due to the complexity and relative scarcity of these conventional assays, point-of-care tests (POCT) might be an attractive alternative in patients with hereditary bleeding disorders...
July 1, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38950595/2023-eberhard-f-mammen-award-announcements-part-ii-young-investigator-awards
#4
JOURNAL ARTICLE
Emmanuel J Favaloro
No abstract text is available yet for this article.
July 1, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38936417/emicizumab-in-type-3-von-willebrand-disease-report-of-a-case-with-an-alloantibody-and-literature-review
#5
JOURNAL ARTICLE
Anna C Giuffrida, Simona M Siboni, Luciano Baronciani, Giovanni Poli, Giorgio Gandini, Flora Peyvandi
Type 3 von Willebrand disease (VWD), the most severe form of VWD, is an inherited recessive bleeding disorder caused by the complete deficiency of von Willebrand factor (VWF). The reported prevalence is 1 per million but varies worldwide according to the frequency of consanguineous marriages. The clinical phenotype is characterized not only by mucocutaneous bleedings, but also by hemarthroses and muscle hematoma, as in patients with moderate hemophilia. Long-term prophylaxis with factor (F)VIII/VWF concentrates is recommended in patients with a history of severe and frequent bleeds...
June 27, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38914118/stress-induced-hypercoagulability-insights-from-epidemiological-and-mechanistic-studies-and-clinical-integration
#6
JOURNAL ARTICLE
Roland von Känel
By integrating findings from comprehensive reviews, meta-analyses, and cutting-edge genetic studies, this article illuminates the significance of stress-induced hypercoagulability in clinical medicine. In particular, the findings from numerous prospective cohort studies indicate that stress and hemostatic factors of a hypercoagulable state are associated with increased incident risk and poor prognosis for atherosclerotic cardiovascular disease and venous thromboembolism. Mendelian randomization studies suggest that these associations are partially causal...
June 24, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38897223/hemostasis-testing-in-the-emergency-department-a-narrative-review
#7
JOURNAL ARTICLE
Henri Thonon, Michael Van Nieuwenhove, Jecko Thachil, Giuseppe Lippi, Michael Hardy, François Mullier
Routine laboratory screening is typically performed at initial evaluation of the vast majority of presentations to the emergency department (ED). These laboratory results are crucial to the diagnostic process, as they may influence up to 70% of clinical decisions. However, despite the usefulness of biological assessments, many tests performed are inappropriate or of doubtful clinical relevance. This overutilization rate of laboratory testing in hospitals, which represents a significant medical-economic burden, ranges from 20 to 67%, with coagulation tests at the top of the list...
June 19, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38889802/laboratory-testing-for-fibrinogen-disorders-from-routine-investigations-to-research-studies
#8
JOURNAL ARTICLE
Anetta Undas
Congenital and acquired fibrinogen disorders often have heterogeneous clinical phenotypes and are challenging from a laboratory perspective. Fibrinogen determination using the Clauss method remains the gold standard, while the reproducibility and significance of the thrombin time and the reptilase time are limited. Molecular testing for causative mutations in fibrinogen genes is now recommended to confirm the diagnosis of congenital fibrinogen disorders. Research assays are used to evaluate alterations to fibrin formation and properties of plasma and purified fibrinogen-derived clots, characterized by fiber thickness, the number of branches, and pore sizes...
June 18, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38889801/patient-perspective-on-disease-burden-and-gene-therapy-for-hemophilia-a-and-b-the-haemvolution-for-patients-italian-survey
#9
JOURNAL ARTICLE
Maria Francesca Mansueto, Sarah Bigi, Marco Follino, Angelo Lupi, Antonio Coppola
Hemophilia is a rare X-linked congenital bleeding disorder due to a deficiency of factor VIII (hemophilia A [HA]) or factor IX (hemophilia B [HB]). Replacement and nonreplacement treatments are available but have limitations. Gene therapy (GT) provides an effective, long-term, single-dose treatment option, now approaching clinical practice. This study aimed to understand patient perspectives on GT for HA and HB in Italy using a qualitative questionnaire distributed through Italian patient associations, addressing patient views on daily life, treatments, unmet needs, quality of life (QoL), and GT for hemophilia...
June 18, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38889800/platelet-pathophysiology-unexpected-new-research-directions
#10
JOURNAL ARTICLE
Alan D Michelson, Andrew L Frelinger Iii, Robin L Haynes, Hannah C Kinney, Thomas Gremmel
No abstract text is available yet for this article.
June 18, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38889799/dosing-intensity-of-anticoagulants-for-the-prevention-and-treatment-of-venous-thromboembolism-and-the-prevention-of-stroke-in-atrial-fibrillation-why-is-there-a-difference
#11
JOURNAL ARTICLE
Jack Hirsh, Alejandro Godoy, Noel C Chan
No abstract text is available yet for this article.
June 18, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38866040/strategies-for-performing-factor-assays-in-the-presence-of-emicizumab-or-other-novel-emerging-hemostatic-agents
#12
JOURNAL ARTICLE
Geoffrey Kershaw
For several decades, therapeutic options for inherited deficiencies of factor VIII or IX (hemophilia A or B, respectively) have largely been the replacement of the missing clotting factor with plasma-derived or recombinant products. Hemostasis laboratories use standard activated partial thromboplastin time (aPTT)-based clotting or chromogenic assays to monitor plasma factor levels to guide therapy. The emergence in the past 10 years of extended half-life replacement products and other novel therapies for hemophilia has led to a reappraisal of assay suitability, with studies of product measurement showing some existing assay types or reagents to be unsuitable for some products...
June 12, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38866039/diagnosis-and-treatment-of-autoimmune-acquired-coagulation-factor-deficiencies-an-evidence-based-review-of-japanese-practice
#13
JOURNAL ARTICLE
Akitada Ichinose, Tsukasa Osaki, Masayoshi Souri
Among the acquired coagulation factor deficiencies, autoimmune coagulation factor deficiencies (AiCFD) are rare and result from autoantibody production against coagulation factors. In Japan, a nationwide survey on AiCFD has been conducted since 2009. Autoimmune factor XIII, factor VIII, von Willebrand factor, factor V, and factor X deficiencies (AiF13D, AiF8D, AiVWFD, AiF5D, and AiF10D, respectively) have been enacted as "designated intractable disease-282." The incidence of AiF8D, AiF13D, and AiF5D was 1.83, 0...
June 12, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38821066/gene-therapy-for-hemophilia-b-achievements-open-issues-and-perspectives
#14
JOURNAL ARTICLE
Giancarlo Castaman, Wolfgang Miesbach
Hemophilia B is the first bleeding disorder for which gene therapy clinical programs began. Presently, adenovirus-associated vectors represent the best means to deliver the transgene, and their administration by intravenous route has been used in recent clinical trials. The natural occurring factor IX (FIX) Padua variant, which allows for a 5- to 8-fold higher activity of FIX, while maintaining a normal protein concentration, was subsequently used to enhance the level of transgene expression. All the recent trials using this variant showed good results, and accumulating data suggest that long-term expression durability could be maintained at a significant hemostatic level...
May 31, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38810964/pleiotropic-effects-of-heparin-and-its-monitoring-in-the-clinical-practice
#15
JOURNAL ARTICLE
Deepa J Arachchillage, Steve Kitchen
Unfractionated heparin (UFH) was uncovered in 1916, has been used as an anticoagulant since 1935, and has been listed in the World Health Organization's Model List of Essential Medicines. Despite the availability of many other anticoagulants, the use of heparin (either low molecular weight heparin [LMWH] or UFH) is still substantial. Heparin has pleotropic effects including anticoagulant and several nonanticoagulant properties such as antiproliferative, anti-inflammatory activity, and anticomplement effects...
May 29, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38759956/contact-activation-where-thrombosis-and-hemostasis-meet-on-a-foreign-surface-plus-a-mini-editorial-compilation-part-xvi
#16
JOURNAL ARTICLE
Helen H Vu, Owen J T McCarty, Emmanuel J Favaloro
No abstract text is available yet for this article.
May 17, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38733984/optimizing-venous-stenting-consensus-recommendations-for-enhanced-management-of-lower-extremity-deep-vein-thrombosis
#17
JOURNAL ARTICLE
Javier Trujillo-Santos, Pablo Demelo-Rodríguez, Alexis Bravo de Laguna-Taboada, Santiago Zubicoa-Ezpeleta, Alejandro Rodríguez-Morata, Ignacio Lojo-Rocamonde, Antoni Riera-Mestre
INTRODUCTION:  Deep vein thrombosis (DVT) poses a complex challenge and often leads to postthrombotic syndrome (PTS), a debilitating complication. The emergence of venous stents offers a potential preventive avenue against this complication. This study aimed to provide consensus recommendations on the use of venous stent for DVT. MATERIALS AND METHODS:  From June to July 2023, 20 internal medicine, angiology and vascular surgery, and vascular and interventional radiology experts were involved in the Delphi process...
May 11, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38733983/thrombophilia-screening-not-so-straightforward
#18
JOURNAL ARTICLE
Gary W Moore
Although inherited thrombophilias are lifelong risk factors for a first thrombotic episode, progression to thrombosis is multifactorial and not all individuals with inherited thrombophilia develop thrombosis in their lifetimes. Consequently, indiscriminate screening in patients with idiopathic thrombosis is not recommended, since presence of a thrombophilia does not necessarily predict recurrence or influence management, and testing should be selective. It follows that a decision to undertake laboratory detection of thrombophilia should be aligned with a concerted effort to identify any significant abnormalities, because it will inform patient management...
May 11, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38733982/nonsevere-hemophilia-the-need-for-a-renewed-focus-and-improved-outcomes
#19
JOURNAL ARTICLE
Gerard Dolan, Karin Fijnvandraat, Peter J Lenting, Cristina Catarino, Michelle Lavin
People with nonsevere hemophilia (PWNSH) are phenotypically more diverse than those with severe hemophilia. Perceptions relating to a "nonsevere" phenotype have contributed to fewer research initiatives, fewer guidelines on optimal management, and a lack of standards for surveillance and clinical assessment for affected individuals. In many cases, episodes of abnormal bleeding could, if investigated, have led to earlier diagnosis. Furthermore, the major recent developments in therapy for hemophilia have largely focused on severe disease and, as a group, PWNSH have not been included in many key clinical trials...
May 11, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38733981/evaluating-diagnostic-algorithms-for-heparin-induced-thrombocytopenia-using-two-combined-automated-rapid-immunoassays
#20
JOURNAL ARTICLE
Anna-Lise Bissola, Yi Zhang, Madison Cranstone, Jane C Moore, Theodore E Warkentin, Donald M Arnold, Ishac Nazy
Heparin-induced thrombocytopenia (HIT) is an autoimmune disorder caused by antibodies against platelet factor 4 (PF4) and heparin complexes. Rapid immunoassays (IAs) for detection of these antibodies mark a milestone in HIT diagnosis, despite a higher false-positive rate compared with functional platelet-activation assays. However, combining different rapid IAs may help to improve their diagnostic specificity. Here, we compared the individual performance of the latex immunoturbidimetric assay (LIA; HemosIL HIT-Ab [PF4-H]; sensitivity 91...
May 11, 2024: Seminars in Thrombosis and Hemostasis
journal
journal
25105
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.